Unique features of the trial include absence of systemic inflammatory response ( SIRS ) criteria as a requirement for inclusion , use of the EAA to confirm endotoxemia as a requisite for treatment , and use of a detailed `` faade '' hemoperfusion event as a blinding mechanism .